• Este endereço de email está protegido contra piratas. Necessita ativar o JavaScript para o visualizar.

Artigos Científicos

terça-feira, 09 janeiro 2018 12:19

A Controlled Trial of Extended-Release Guanfacine and Psychostimulants on Executive Function and ADHD

Rate this item
(0 votes)

Judy P. M. van Stralen1

1
Center for Pediatric Excellence, Ottawa, Ontario, Canada

Journal of Attention Disorders: SAGE Journals

January 9, 2018


ABSTRACT:

Objective: To evaluate the effectiveness of guanfacine extended-release (GXR) versus placebo as adjunct therapy to usual care stimulant therapy in improving executive function in children aged 6 to 12 years diagnosed with ADHD.

Method: In this single center, double-blind placebo-controlled crossover trial, subjects continued to take their psychostimulant and were randomly assigned at baseline to receive active treatment or placebo first. Efficacy measures included Behavioural Rating Inventory of Executive Function (BRIEF-P), ADHD Rating Scale IV (ADHD-RS IV), and Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) scales. Safety measures included adverse events and vital signs.

Results: Significant benefits of GXR plus psychostimulant were observed on BRIEF-P (p value = .0392), ADHD-RS-IV (p < .0001), CGI-S (p = .0007), and CGI-I (p = .003). There were no serious adverse events and no new safety signals.

Conclusion: Use of GXR as adjunctive therapy to stimulant therapy significantly improves executive function in children with ADHD.


Ver artigo completo...


A Direção da SPDA - Sociedade Portuguesa de Défice de Atenção

Read 142 times Last modified on quinta-feira, 12 março 2020 11:36
© 2020 SPDA - Sociedade Portuguesa de Défice de Atenção. All Rights Reserved. Design by BID-lab